Assessment of Quality of Life and Outcomes in Patients Treated With Stereotactic Body Radiotherapy (SBRT) for Inoperable Renal Cell Carcinoma (RCC): A Multicenter Phase II Study
Condition: Renal Cell Carcinoma
Study Type: Interventional
Clinical Trials Identifier NCT 8-digits: NCT05023265
Sponsor: Sunnybrook Health Sciences Centre
Eligibility:
- Age: minimum 18 Years maximum N/A
- Gender: All
Inclusion Criteria:
- Patients ≥18 years old
- Newly diagnosed RCC by biopsy (preferred) or radiologic evidence of growth on surveillance over two consecutive assessments (6-12 months)
- Primary lesion >3 cm, or recurrent lesion following local ablative therapy
- Medically inoperable or patient who refuses surgery following assessment by experienced urologist, and discussed in a multidisciplinary setting
- ECOG 0-2
- Written informed consent
- Participants must be able to understand the English-language or with the aid of a translator
Exclusion Criteria:
- Primary Lesion >20cm
- Evidence of distant metastatic disease
- Previous abdominal RT in vicinity of kidney preventing definitive SBRT
- History of major radiosensitivity syndrome
- Second invasive malignancy within the past 3 years (excluding non-melanomatous skin cancer)
- Currently pregnant or lactating
View trial on ClinicalTrials.gov